Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2020)
18 slides from Nova Eye Medical's shareholder meeting presentation, Nov 27, 2020
Slide 1: Annual General Meeting Presentation and Update
1 For personal use only NOVA EYE MEDICAL LIMITED (FORMERLY ELLEX MEDICAL LASERS LIMITED) ANNUAL GENERAL MEETING (ASX:EYE) PRESENTATION AND UPDATE 27 November 2020
Slide 2: Chairman Address
2 For personal use only CHAIRMAN ADDRESS VICTOR PREVIN
Slide 3: Investor Presentation
3 For personal use only INVESTOR PRESENTATION TOM SPURLING, DIRECTOR
Slide 4: Disclaimer
4 For personal use only DISCLAIMER: This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy
Slide 5: Recent Financial Highlights
5 RECENT FINANCIAL HIGHLIGHTS For personal use only $100M $61M CASH SALE RETURN TO SHAREHOLDERS TRANSACTION ▪ Sale of the Ellex brand and ▪ $61.0 million return of capital capital equipment business to and dividend from transaction Lumibird for $100 million in proceeds to shareholders cash (complete
Slide 6: FY20 Company Snapshot
6 FY20 COMPANY SNAPSHOT (ASX:EYE) For personal use only Pro-Forma Pro-Forma Market Capitalisation1 Cash2 Enterprise Value3 Global Employees $47 million $26.5 million $16.5 million 50 FY20 Cash Outflow from Directors & Mgt. Own FY20 Revenue4 FY20 EBITDA5 Continuing Operations 14% $12.8 million -$5.8
Slide 7: Nova Eye Business
7 NOVA EYE BUSINESS For personal use only Rebranding of the company to Nova Eye on 30 June 2020, now focused on consumable surgical devices for glaucoma – and leveraging these technologies for future growth and development. ▪ Grow market penetration of our proprietary iTrack™ and Molteno3® WE ARE CO
Slide 8: About Glaucoma
8 ABOUT GLAUCOMA For personal use only Glaucoma is the leading cause of blindness in the developed world – but up to 50% of patients with glaucoma do not realise they have the disease and >50% of diagnosed patients are non compliant . ▪ Glaucoma is a group of diseases WHAT CAUSES GLAUCOMA? that caus
Slide 9: Nova Eye Glaucoma Opportunity
9 NOVA EYE GLAUCOMA OPPORTUNITY For personal use only Nova Eye has been reorganised to focus on glaucoma treatment. GROWING MARKET SUSTAINABLE BUSINESS With a proprietary product The glaucoma consumable surgical portfolio and an established Aging global population is driving devices market is the fa
Slide 10: Redefining Glaucoma Treatment
10 REDEFINING GLAUCOMA TREATMENT For personal use only Glaucoma management is in a period of renaissance with the realisation that pharmaceuticals do not represent the best treatment option. ▪ Topical medications are considered standard of care but nonadherence is ubiquitous 60% ▪ Device solutions a
Slide 11: iTrack microcatheter
11 For personal use only A unique, patented product that provides “angioplasty of the eye” ; a unique point of difference in the fast- growing, minimally invasive glaucoma surgery (MIGS) market. ▪ Our proprietary iTrack ™ technology is a key player in the fast-growing MIGS market ▪ The iTrack ™ is a
Slide 12: Molteno3 partnership and acquisition
12 For personal use only Molteno, the inventors of Glaucoma Drainage Devices, have partnered with Nova Eye ▪ Acquired on 3 August 2020 for ▪ Nova Eye Medical will leverage its NZ$1.05m (A$0.99m) in cash, current sales and marketing representing an acquisition infrastructure to support Molteno3® mult
Slide 13: Our Global Presence
13 OUR GLOBAL PRESENCE For personal use only Nova Eye Medical has approximately 50 staff globally, supported by a network of distributors in more than 50 countries. GERMANY Nova Eye USA Medical GmbH NEW ZEALAND Nova Eye, Inc Molteno Ophthalmic Ltd German Sales Headquarters USA Molteno3® Manufacturin
Slide 14: FY20 Financial Performance
14 FY20 FINANCIAL PERFORMANCE For personal use only Despite a reduction in surgical volumes due to the COVID-19 pandemic, the implementation of a number of cost management initiatives during the period delivered an improved EBITDA-level performance. $000’s ▪ Worldwide iTrack™ unit volumes FY19 FY20
Slide 15: AlphaRET and 2RT Project
15 For personal use only AlphaRET Pty Ltd is a newly established wholly owned subsidiary of Nova Eye Medical (ASX:EYE), established in October 2020 to facilitate the commercial development of the Company’s proprietary 2RT® Project. ▪ Current AMD therapy only ▪ Expansion of 2RT® indication for treats
Slide 16: FY21 Sales Performance
16 FY21 SALES PERFORMANCE For personal use only Despite continued uncertainty in global markets arising from COVID-19, focused sales management teamed with an experienced, dedicated glaucoma sales force has demonstrated sales growth particularly in USA both over the prior comparative period and the
Slide 17: Our Outlook
17 OUR OUTLOOK For personal use only Nova Eye Medical has a number of objectives for the 2021 financial year to support growth of our core glaucoma business, and to execute the 2RT ® opportunity. 1 GLAUCOMA SALES FOCUS: investment into iTrack™ and Molteno3® market development in preparation for aggr
Slide 18: Contacts
18 CONTACTS For personal use only Mr Tom Spurling Dr Tom Duthy Ms Kate Hunt Director Investor Relations and Head of Marketing +61 417 818 658 Corporate Development +61 404 080 679 tspurling@nova-eye.com +61 402 493 727 khunt@nova-eye.com tduthy@nova-eye.com C O M P AN Y INVESTORS MEDIA
Nova Eye Medical — Shareholder Meeting (November 2020) on 6ix